Key result
A novel fully automated digital immunoassay for cardiac troponin I achieved a limit of detection of 0.01 ng/L and detected significantly higher concentrations in heart failure patients.
A novel ultrasensitive digital immunoassay for cTnI demonstrates a 2-log increase in sensitivity compared to contemporary assays, enabling detection in all healthy individuals and showing correlation with heart failure severity.
Answers are grounded in this paper and cite their sources.
May enable routine troponin monitoring; leaves open clinical utility pending larger validation studies.
BACKGROUND: The association between increases in cardiac troponin and adverse cardiac outcomes is well established. There is a growing interest in exploring routine cardiac troponin monitoring as a potential early indicator of adverse heart health trends. Prognostic use of cardiac troponin measurements requires an assay with very high sensitivity and outstanding analytical performance. We report development and preliminary validation of an investigational assay meeting these requirements and demonstrate its applicability to cohorts of healthy individuals and patients with heart failure. METHODS: On the basis of single molecule array technology, we developed a 45-min immunoassay for cardiac troponin I (cTnI) for use on a novel, fully automated digital analyzer. We characterized its analytical performance and measured cTnI in healthy individuals and heart failure patients in a preliminary study of assay analytical efficacy. RESULTS: The assay exhibited a limit of detection of 0.01 ng/L, a limit of quantification of 0.08 ng/L, and a total CV of 10% at 2.0 ng/L. cTnI concentrations were well above the assay limit of detection for all samples tested, including samples from healthy individuals. cTnI was significantly higher in heart failure patients, and exhibited increasing median and interquartile concentrations with increasing New York Heart Association classification of heart failure severity. CONCLUSIONS: The robust 2-log increase in sensitivity relative to contemporary high-sensitivity cardiac troponin immunoassays, combined with full automation, make this assay suitable for exploring cTnI concentrations in cohorts of healthy individuals and for the potential prognostic application of serial cardiac troponin measurements in both apparently healthy and diseased individuals.
No takes yet. Share an insight, caveat, or question.
Jarolı́m et al. (2015) studied Healthy individuals and heart failure. Fully automated ultrasensitive digital immunoassay for cardiac troponin I was evaluated on Analytical performance (limit of detection, limit of quantification, total CV) and cTnI concentrations. A novel fully automated digital immunoassay for cardiac troponin I achieved a limit of detection of 0.01 ng/L and detected significantly higher concentrations in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: